Impact of polymorphisms of pharmacokinetics‐related genes and the inflammatory response on the metabolism of voriconazole
Open Access
- 23 February 2022
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 10 (2) , e00935
Abstract
The effects of inflammatory responses and polymorphisms of the genes encoding cytochrome P450 (CYP) (CYP2C19 and CYP3A5), flavin‐containing monooxygenase 3 (FMO3), pregnane X receptor (NR1I2), constitutive androstane receptor (NR1I3), and CYP oxidoreductase (POR) on the ratio of voriconazole (VRCZ) N‐oxide to VRCZ (VNO/VRCZ) and steady‐state trough concentrations (C0h) of VRCZ were investigated. A total of 56 blood samples were collected from 36 Japanese patients. Results of multiple linear regression analyses demonstrated that the presence of the extensive metabolizer CYP2C19 genotype, the dose per administration, and the presence of the NR1I2 rs3814057 C/C genotype were independent factors influencing the VNO/VRCZ ratio in patients with CRP levels of less than 40 mg/L (standardized regression coefficients (SRC) = 0.448, −0.301, and 0.390, respectively; all p < .05). With regard to the concentration of VRCZ itself, in addition to the above factors, the presence of the NR1I2 rs7643645 G/G and rs3814055 T/T genotypes were found to be independent factors influencing the VRCZ C0h in these patients (SRC = −0.430, 0.424, −0.326, 0.406 and −0.455, respectively; all p < .05). On the contrary, in patients with CRP levels of at least 40 mg/L, no independent factors were found to affect VNO/VRCZ and VRCZ C0h. Inflammatory responses, and CYP2C19 and NR1I2 polymorphisms may be useful information for the individualization of VRCZ dosages.Keywords
Funding Information
- Japan Society for the Promotion of Science (18K06778)
This publication has 47 references indexed in Scilit:
- Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug MonitoringJournal of Infection and Chemotherapy, 2013
- The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled TrialClinical Infectious Diseases, 2012
- Antifungal prophylaxis in haematology patients: the role of voriconazoleClinical Microbiology and Infection, 2012
- Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotypeBritish Journal of Clinical Pharmacology, 2009
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver MicrosomesDrug Metabolism and Disposition, 2008
- The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole AntifungalsClinical Pharmacokinetics, 2008
- The role of nuclear receptors in pharmacokinetic drug–drug interactions in oncologyCancer Treatment Reviews, 2007
- Pharmacokinetic/Pharmacodynamic Profile of VoriconazoleClinical Pharmacokinetics, 2006
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002